Committee for Proprietary Medicinal Products (CPMP) Committee for Proprietary Medicinal Products (CPMP) Successful treatment of molybdenum cofactor deficiency type A with cPMP Committee for proprietary medicinal products (CPMP) points to consider on adjustment for baseline covariates Guideline on Medicinal Products for the Treatment of Alzheimer's Disease and Other Dementias (CPMP/EWP/553/95 Rev.1) Good Clinical Practice for Trials on Medicinal Products in the European Community: CPMP Working Party on Efficacy of Medicinal Produ... Good Clinical Practice for Trials on Medicinal Products in the European Community: CPMP Working Party on Efficacy of Medicinal Produ... SUCCESSFUL TREATMENT OF MOLYBDENUM COFACTOR DEFICIENCY TYPE A WITH CYCLIC PYRANOPTERIN MONOPHOSPHATE (cPMP) IN FIVE PATIENTS Erratum: Committee for proprietary medicinal products (CPMP): Points to consider on adjustment for baseline covariates (Statistics i... A TritonX-100-split Virion Influenza Vaccine is Safe and Fulfills the Committee for Proprietary Medicinal Products (CPMP) Recommenda...
